Vera Therapeutics (VERA) catalysts

Upcoming FDA decisions and readouts we track for Vera Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 14 Sep 2026

FreeBioList has 1 catalyst on record for Vera Therapeutics (VERA, listed on Nasdaq), all now decided. It concerns Atacicept (IgA nephropathy).

Decided and on record:

Atacicept, PDUFA date: Approved 7 July 2026, on the PDUFA date.

Each outcome links to the filing or notice that reported it in the table below.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 14 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: VERA
Next catalyst: —
Type: —
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Vera Therapeutics VERA · Nasdaq	Atacicept	IgA nephropathy	07 Jul 2026 92d ago	PDUFA date	Verified	8-K ↗	Yes
Notes — FDA granted TRUTAKNA (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression, per the 8-K filed the same day as the PDUFA date. Outcome — Approved 7 July 2026, on the PDUFA date — FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression. Source: 8-K, filed 07 Jul 2026 · verified 14 Sep 2026

Companies working on related conditions

Climb Bio (CLYM)IgA nephropathy / autoimmune (CD19 antibody)
Jade Biosciences (JBIO)IgA nephropathy (APRIL antibody); Rheumatoid arthritis; Dermatomyositis
Zai Lab Ltd. (ZLAB)IgA nephropathy